$50 Million

Jounce Therapeutics

At-the-market Offering

Jounce Therapeutics
Jounce Therapeutics is an immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, the Company can prioritize targets and identify related biomarkers to match the right therapy to the right patients. The Company believes that through enriched clinical trial designs their approach will also lead to shortened development timelines. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in many solid tumors. Jounce Therapeutics, Inc. (“Jounce” or the “Company”) is an immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, the Company can prioritize targets and identify related biomarkers to match the right therapy to the right patients. The Company believes that through enriched clinical trial designs their approach will also lead to shortened development timelines. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in many solid tumors. Jounce Therapeutics, Inc. (“Jounce” or the “Company”) is an immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, the Company can prioritize targets and identify related biomarkers to match the right therapy to the right patients. The Company believes that through enriched clinical trial designs their approach will also lead to shortened development timelines. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in many solid tumors.